Inovio COVID-19 vaccine

COVID-19 vaccine candidate

  • DB15693
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
  • COVID-19 (disease)
  • SARS-CoV-2 (virus)
  • Cases
  • Deaths
virus icon COVID-19 portal
  • v
  • t
  • e

Inovio COVID-19 vaccine is a COVID-19 vaccine candidate developed by Inovio Pharmaceuticals.

History

In February 2020 after receiving details of the genetic sequence of the coronavirus, Inovio announced that it had produced a preclinical DNA-based vaccine as a potential therapy for COVID-19.[1][2] Inovio is in competition to develop a coronavirus vaccine with numerous other companies, which were conducting preclinical or early-stage human research on more than 170 vaccine candidates, as of late June.[3] In April 2020, Inovio began a Phase I trial of the COVID-19 vaccine candidate, INO-4800.[4]

Clinical trials

Inovio is collaborating with Beijing Advaccine Biotechnology Co., a Chinese biotech firm,[2] in order to speed its acceptance by regulatory authorities in China, with plans to begin human clinical trials of a candidate vaccine in China during the first half of 2020.[5][6] Inovio has partnerships with manufacturers to scale up production of a vaccine if preliminary efficacy trials are successful.[2] In April 2020, the company began human Phase I safety studies of its lead vaccine (INO-4800) in the United States, and a Phase I-II trial in South Korea, to test for immunization against the COVID-19 virus.[5][7]

In early June, Inovio partnered with the International Vaccine Institute and Seoul National University, South Korea, to advance human research on INO-4800 in a Phase I-II safety and efficacy trial to be conducted on 120 participants at Seoul National University Hospital beginning in June.[8] The trial is funded by the Coalition for Epidemic Preparedness Innovations and supported by the Korea Centers for Disease Control and Prevention and the Korea National Institute of Health.[8]

On April 23, 2021 Inovio said the U.S. Department of Defense discontinued funding for the phase III portion of an ongoing trial of its COVID-19 vaccine candidate, INO-4800, in light of the broad availability of other COVID-19 vaccines in the U.S. The news followed recent phase I data showing '4800 performed about in line with already available competitors against the existing SARS-CoV-2 variants.[9] NOVIO's global Phase 3 efficacy trial receives authorization to proceed from Brazil; other countries to follow

On August 26, 2021 Inovio's global Phase 3 efficacy trial receives authorization to proceed from Brazil.[10]

On October 26, 2021 The World Health Organization launched a Global Covid-19 Trial termed as the Solidarity Trial Vaccines. Inovio INO-4800 was chosen as the first DNA Vaccine to be introduced in the largest vaccine trial in history. The Countries of Colombia, Mali and the Philippines announced participation with many other countries yet to be named. The WHO is directly financing this trial.[11]

On December 14, 2021 Inovio released Clinical Data on Phase 1 and 2 trials held in the USA. The Data showed zero Level 3 Adverse Events. Conclusion INO-4800 appears safe and tolerable as a primary series and as a booster with the induction of both humoral and cellular immune responses. In addition to eliciting neutralizing antibodies, INO-4800 also induced T cell immune responses as demonstrated by IFNγ ELISpot. Finally, as a homologous booster, INO-4800, when administered 6-10.5 months following the primary series, resulted in an increased immune response without increase in reactogenicity.[12]


References

  1. ^ Linnane C (8 March 2020). "Inovio shares rally after biotech says human trials of coronavirus vaccine will start in April". MarketWatch. Retrieved 8 March 2020.
  2. ^ a b c Freeman M. "Is a vaccine for the coronavirus coming? Inovio says it has designed one in San Diego". Los Angeles Times. Retrieved 17 February 2020.
  3. ^ "COVID-19 vaccine tracker (Select vaccine tab)". Milken Institute. 22 June 2020. Retrieved 23 June 2020.
  4. ^ Clinical trial number NCT04336410 for "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers" at ClinicalTrials.gov
  5. ^ a b Le TT, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S (May 2020). "The COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. PMID 32273591.
  6. ^ Mazumdar T (30 January 2020). "Coronavirus: Scientists race to develop a vaccine". BBC News – Health. Retrieved 3 February 2020.
  7. ^ "IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea". International Vaccine Institute. 16 April 2020. Retrieved 23 April 2020.
  8. ^ a b "IVI and SNU partner to trial Inovio Covid-19 vaccine in Korea". Clinical Trials Arena. 5 June 2020. Retrieved 8 June 2020.
  9. ^ "Inovio shares sink as DoD pulls support for phase III portion of COVID-19 vaccine study | 2021-04-23 | BioWorld". www.bioworld.com. Retrieved 6 March 2024.
  10. ^ [INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800 https://ir.inovio.com/news-releases/news-releases-details/2021/INOVIO-Receives-Authorization-to-Conduct-Phase-3-Efficacy-Trial-of-its-COVID-19-DNA-Vaccine-Candidate-INO-4800/default.aspx]
  11. ^ "Global Solidarity Trial of COVID-19 vaccines". www.who.int. Retrieved 6 March 2024.
  12. ^ [ 571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster https://www.researchgate.net/publication/356795013_571_Safety_and_Immunogenicity_of_INO-4800_a_COVID-19_DNA_Vaccine_as_a_Primary_Series_and_Booster]

External links

Scholia has a profile for INO-4800 (Q96695266).
  • v
  • t
  • e
Pre-pandemic
2020
2021
2022
2023 and after
Africa
Northern
Eastern
Southern
Central
Western
Asia
Central/North
East
Mainland China
South
India
By location
Southeast
Malaysia
Philippines
West
Europe
United Kingdom
By location
Eastern
Western Balkans
European Union
EFTA countries
Microstates
North
America
Atlantic
Canada
Caribbean
Countries
British Overseas Territories
Caribbean Netherlands
French West Indies
US insular areas
Central America
United States
responses
By location
Oceania
Australia
New Zealand
South
America
Others
Culture and
entertainment
Arts and
cultural heritage
Education
By country
Sports
By country
By sport
Society
and rights
Social impact
Labor
Human rights
Legal
Minority
Religion
Economic
By country
By industry
Supply and trade
Financial markets
Information
Misinformation
Politics
Political impact
Protests
International relations
Language
Others
Health issues
Medical topics
Testing and
epidemiology
Apps
Prevention
Vaccines
Topics
Authorized
DNA
Inactivated
mRNA
Subunit
Viral vector
Virus-like particles
In trials
Attenuated
  • COVI-VAC (United States)
DNA
Inactivated
RNA
Subunit
Viral vector
Virus-like particles
Deployment
by location
Africa
Asia
Europe
North America
Oceania
South America
Others
Treatment
Monoclonal antibodies
Small molecule antivirals
Specific
General
Institutions
Hospitals and
medical clinics
Mainland China
Others
Organizations
Global
By location
Health
institutes
Pandemic
institutes
Relief funds
People
Medical
professionals
Researchers
Officials
WHO
  • Tedros Adhanom
  • (Director-General of the WHO)
  • Bruce Aylward
  • (Team lead of WHO-China COVID-19 mission)
  • Maria Van Kerkhove
  • (Technical Lead for COVID-19 response)
  • Michael J. Ryan
  • (Executive Director of the WHO Health Emergencies Programme)
By location
Others
Deaths
Data (templates)
Global
Africa
  • Algeria
  • Angola
  • Benin
  • Botswana
  • Burkina Faso
  • Burundi
  • Cameroon
  • Comoros
  • Egypt
  • Eswatini
  • Ethiopia
  • Ghana
    • cases chart
  • Ivory Coast
  • Kenya
  • Libya
  • Malawi
  • Mali
  • Mauritania
  • Mauritius
  • Morocco (including occupied Western Sahara)
  • Mozambique
  • Namibia
  • Nigera
    • cases chart
  • São Tomé and Príncipe
  • Senegal
  • Seychelles
  • Sierra Leone
  • South Africa
    • cases chart
  • South Sudan
  • Sudan
  • Tanzania
  • Togo
  • Tunisia
  • Uganda
  • Zambia
  • Zimbabwe
    • cases chart
Americas
  • Argentina
  • Bolivia
  • Brazil
  • Canada
    • by province
    • vaccinations by province
  • Chile
    • by commune
  • Colombia
  • Costa Rica
    • cases chart
  • Cuba
  • Dominican Republic
  • Ecuador
  • El Salvador
  • Guatemala
  • Haiti
  • Honduras
  • Mexico
    • cases chart
  • Nicaragua
  • Panama
  • Paraguay
  • Peru
  • United States
    • by state
  • Uruguay
  • Venezuela
Asia
  • Afghanistan
  • Armenia
    • Artsakh
  • Azerbaijan
  • Bahrain
  • Bangladesh
    • by division
  • Bhutan
    • cases chart
  • Brunei
  • Cambodia
    • cases chart
    • summary
  • China
    • cases chart
    • confirmed per capita
    • lockdowns
    • by province
    • Hong Kong
    • Macau
  • Cyprus
  • East Timor
  • Egypt
  • Georgia
  • India
  • Indonesia
    • cases chart
  • Iran
    • cases chart
  • Iraq
  • Israel
    • cases chart
  • Japan
    • cases chart
  • Jordan
  • Kazakhstan
  • Kuwait
    • cases chart
  • Kyrgyzstan
  • Laos
  • Lebanon
  • Malaysia
    • cases chart
    • charts
  • Myanmar
    • cases chart
    • summary
  • Nepal
    • cases chart
  • Oman
    • cases chart
  • Pakistan
    • cases chart
  • Philippines
    • cases chart
    • areas of quarantine
    • vaccinations chart
  • Qatar
  • Russia
    • cases chart
    • by federal subject
    • North Asia
  • Saudi Arabia
  • Singapore
  • South Korea
    • cases chart
    • vaccinations charts
  • Sri Lanka
  • Syria
  • Taiwan
    • vaccination charts
  • Tajikistan
  • Thailand
    • cases chart
  • Turkey
    • cases chart
  • United Arab Emirates
    • cases chart
  • Uzbekistan
    • cases chart
  • Vietnam
    • statistics charts
  • Yemen
Europe
  • Albania
  • Austria
    • cases chart
  • Belarus
  • Belgium
    • cases chart
  • Bosnia and Herzegovina
  • Bulgaria
    • cases chart
  • Croatia
  • Cyprus
  • Czech Republic
  • Denmark
    • cases chart
    • Faroe Islands
  • Estonia
    • cases chart
  • Finland
  • France
    • cases chart
  • Germany
    • cases chart
  • Greece
  • Hungary
  • Iceland
    • cases chart
  • Ireland
    • cases chart
  • Italy
    • cases chart
    • statistics charts
    • vaccinations chart
  • Kosovo
  • Latvia
  • cases chart
  • Lithuania
    • cases chart
  • Luxembourg
  • Malta
  • Moldova
  • Monaco
  • Montenegro
  • Netherlands
  • North Macedonia
  • Norway
    • cases chart
  • Poland
    • cases chart
    • by voivodeship
  • Portugal
    • cases chart
  • Romania
  • cases chart
  • Russia
    • cases chart
    • by federal subject
    • North Asia
  • San Marino
  • Serbia
  • Slovakia
    • cases chart
    • by region
  • Slovenia
    • cases chart
  • Spain
    • cases chart
  • Sweden
    • cases chart
  • Switzerland
    • cases chart
  • Turkey
    • cases chart
  • Ukraine
  • United Kingdom
    • Scotland
      • 2020
      • 2021
    • Gibraltar
    • vaccinations chart
      • daily
      • by nation
  • Vatican City
Oceania
  • Australia
    • by state/territory
  • Fiji
  • French Polynesia
  • New Caledonia
  • New Zealand
  • Papua New Guinea
  • Solomon Islands
Others
  • Cruise ships
    • Diamond Princess
  • v
  • t
  • e
Development
Classes
Administration
Vaccines
Bacterial
Viral
Protozoan
Helminthiasis
Other
Inventors/
researchers
Controversy
Related
Portals:
  • icon Medicine
  • icon Viruses
  • virus icon COVID-19